Skip to main content
Article thumbnail
Location of Repository

Hsp90 governs dispersion and drug resistance of fungal biofilms

By N. Robbins, P. Uppuluri, J. Nett, R. Rajendran, G. Ramage, J.L. Lopez-Ribot, D. Andes and L.E. Cowen

Abstract

Fungal biofilms are a major cause of human mortality and are recalcitrant to most treatments due to intrinsic drug resistance. These complex communities of multiple cell types form on indwelling medical devices and their eradication often requires surgical removal of infected devices. Here we implicate the molecular chaperone Hsp90 as a key regulator of biofilm dispersion and drug resistance. We previously established that in the leading human fungal pathogen, Candida albicans, Hsp90 enables the emergence and maintenance of drug resistance in planktonic conditions by stabilizing the protein phosphatase calcineurin and MAPK Mkc1. Hsp90 also regulates temperature-dependent C. albicans morphogenesis through repression of cAMP-PKA signalling. Here we demonstrate that genetic depletion of Hsp90 reduced C. albicans biofilm growth and maturation in vitro and impaired dispersal of biofilm cells. Further, compromising Hsp90 function in vitro abrogated resistance of C. albicans biofilms to the most widely deployed class of antifungal drugs, the azoles. Depletion of Hsp90 led to reduction of calcineurin and Mkc1 in planktonic but not biofilm conditions, suggesting that Hsp90 regulates drug resistance through different mechanisms in these distinct cellular states. Reduction of Hsp90 levels led to a marked decrease in matrix glucan levels, providing a compelling mechanism through which Hsp90 might regulate biofilm azole resistance. Impairment of Hsp90 function genetically or pharmacologically transformed fluconazole from ineffectual to highly effective in eradicating biofilms in a rat venous catheter infection model. Finally, inhibition of Hsp90 reduced resistance of biofilms of the most lethal mould, Aspergillus fumigatus, to the newest class of antifungals to reach the clinic, the echinocandins. Thus, we establish a novel mechanism regulating biofilm drug resistance and dispersion and that targeting Hsp90 provides a much-needed strategy for improving clinical outcome in the treatment of biofilm infections

Publisher: Public Library of Science
Year: 2011
OAI identifier: oai:eprints.gla.ac.uk:57111
Provided by: Enlighten

Suggested articles

Citations

  1. (2009). 17 AAG for HSP90 inhibition in cancer–from bench to bedside.
  2. (2005). A contact-activated kinase signals Candida albicans invasive growth and biofilm development.
  3. (2010). A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90.
  4. (2011). An easy and economical in vitro method for the formation of Candida albicans biofilms under continuous conditions of flow.
  5. (2010). An insight into the antifungal pipeline: selected new molecules and beyond.
  6. (2010). AntiCandida-biofilm activity of micafungin is attenuated by voriconazole but restored by pharmacological inhibition of Hsp90-related stress responses.
  7. (2001). Aspergillosis case-fatality rate: systematic review of the literature.
  8. (2008). Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells.
  9. (2006). Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1.
  10. (2004). Beta-Dglucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome.
  11. (2009). Biofilm matrix regulation by Candida albicans Zap1.
  12. (2006). Biofilms and their role in the resistance of pathogenic Candida to antifungal agents.
  13. (2005). Candida albicans biofilmdefective mutants.
  14. (2004). Candida albicans biofilms: a developmental state associated with specific and stable gene expression patterns.
  15. (2006). Candida biofilms on implanted biomaterials: a clinically significant problem.
  16. (2004). Candida infections of medical devices.
  17. (2002). Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death.
  18. (2009). Design of a simple model of Candida albicans biofilms formed under conditions of flow: development, architecture, and drug resistance.
  19. (2004). Development and characterization of an in vivo central venous catheter Candida albicans biofilm model.
  20. (2007). Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus.
  21. (2010). Dispersion as an important step in the Candida albicans biofilm developmental cycle.
  22. (2007). Epidemiology of invasive candidiasis: a persistent public health problem.
  23. (2010). Epidemiology of invasive mycoses in North America.
  24. (2005). Evolution of antifungal-drug resistance: mechanisms and pathogen fitness.
  25. (1985). Extracellular polymer of Candida albicans: isolation, analysis and role in adhesion.
  26. (2006). Genetic architecture of Hsp90-dependent drug resistance.
  27. (2010). Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan.
  28. (2011). Genetic control of Candida albicans biofilm development.
  29. (2006). Genetics and genomics of Candida albicans biofilm formation.
  30. (2009). Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease.
  31. (2010). Heat shock protein 90 as a drug target against protozoan infections: biochemical characterization of HSP90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug.
  32. (2006). How to build a biofilm: a fungal perspective.
  33. (2010). HSP90 at the hub of protein homeostasis: emerging mechanistic insights.
  34. (2009). Hsp90 orchestrates temperature-dependent Candida albicans morphogenesis via Ras1-PKA signaling.
  35. (2005). Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309: 2185–2189. Regulation of Fungal Biofilms by
  36. (2001). Hsp90: a specialized but essential proteinfolding tool.
  37. (2002). Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms.
  38. (2003). Isolation and partial characterization of Hsp90 from Candida albicans.
  39. (2003). Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols.
  40. (2002). Molecular basis of resistance to azole antifungals.
  41. (2009). Our current understanding of fungal biofilms.
  42. (2010). PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of
  43. (2001). Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients.
  44. (2007). Putative role of beta-1,3 glucans in Candida albicans biofilm resistance.
  45. (2011). Regulatory circuitry governing fungal development, drug resistance, and disease.
  46. (2007). Role for cell density in antifungal drug resistance in Candida albicans biofilms.
  47. (2005). Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.
  48. (2001). Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms.
  49. (2008). Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
  50. (2006). Structure and mechanism of the Hsp90 molecular chaperone machinery.
  51. (2008). Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms.
  52. (2010). Systematic screens of a Candida albicans homozygous deletion library decouple morphogenetic switching and pathogenicity.
  53. (2010). Targeting the dynamic HSP90 complex in cancer.
  54. (2002). The direct cost and incidence of systemic fungal infections.
  55. (2005). The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis.
  56. (2008). The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype.
  57. (2002). The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans.
  58. (2010). The transcriptional regulator Nrg1p controls Candida albicans biofilm formation and dispersion.
  59. (2001). Trends in mortality due to invasive mycotic diseases in the United States,

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.